C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.17% | 138.17% | 58.75% | 38.75% | 350.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.17% | 138.17% | 58.75% | 38.75% | 350.68% |
| Cost of Revenue | 10.29% | 20.14% | 6.98% | 12.32% | -20.63% |
| Gross Profit | -67.99% | -1.74% | -0.76% | 4.63% | 56.91% |
| SG&A Expenses | -9.57% | -9.31% | 0.74% | 11.73% | -5.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.53% | 10.91% | 5.40% | 12.16% | -16.86% |
| Operating Income | -32.92% | 2.08% | -0.75% | -1.57% | 42.92% |
| Income Before Tax | -46.87% | 7.19% | 0.10% | 5.25% | 50.68% |
| Income Tax Expenses | -- | -- | -52.71% | -- | -- |
| Earnings from Continuing Operations | -46.87% | 7.19% | 0.52% | 8.77% | 50.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.87% | 7.19% | 0.52% | 8.77% | 50.68% |
| EBIT | -32.92% | 2.08% | -0.75% | -1.57% | 42.92% |
| EBITDA | -32.83% | 2.13% | -0.63% | -1.61% | 43.43% |
| EPS Basic | -42.29% | 10.33% | 27.78% | 35.51% | 64.83% |
| Normalized Basic EPS | -28.53% | 1.90% | 27.26% | 31.39% | 60.90% |
| EPS Diluted | -42.29% | 10.33% | 27.78% | 35.51% | 64.83% |
| Normalized Diluted EPS | -28.53% | 1.90% | 27.26% | 31.39% | 60.90% |
| Average Basic Shares Outstanding | 3.19% | 3.51% | 37.76% | 41.48% | 40.25% |
| Average Diluted Shares Outstanding | 3.19% | 3.51% | 37.76% | 41.48% | 40.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |